Wiskott-Aldrich syndrome protein (WASp) signaling in the oncogenesis of T cell lymphomas
Wiskott-Aldrich syndrome protein (WASp) signaling in the oncogenesis of T cell lymphomas
批准号:
9751816
负责人:
Carlos A. Murga-Zamalloa
金额:
$2.41万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-25 至 2019-12-31
关键词:
ActinsAdhesionsAnchorage-Independent GrowthBiological AssayCell LineCellsChemotactic FactorsChemotaxisClinical SkillsClinical TrialsCollagenDataDevelopmentDevelopment PlansDiagnosisDiseaseDown-RegulationEndothelial CellsExtracellular Signal Regulated KinasesGATA3 geneGoalsGrowthIndividualIntercellular adhesion molecule 1Ki-1 Large-Cell LymphomaKnockout MiceKnowledgeLymphocyteLymphocyte ActivationLymphomaMAPK3 geneMalignant NeoplasmsMediatingMitogen-Activated Protein KinasesMolecularNeoplasm MetastasisNon-Hodgkin&aposs LymphomaOncogenicPathway interactionsPatient CarePatientsPeripheralPeripheral ResistancePharmaceutical PreparationsPhosphorylationPhysiciansPlayProteinsRelapseResearchResearch Project GrantsResistanceRoleScientistSignal PathwaySignal TransductionSignaling ProteinSpecific qualifier valueStructureSurfaceT-Cell DevelopmentT-Cell LymphomaT-LymphocyteTechnical ExpertiseTestingTherapeuticTranslational ResearchTreatment EfficacyTumor Cell InvasionUnited StatesVascular Cell Adhesion Molecule-1WaspsWiskott-Aldrich SyndromeWritingcancer typecareercareer developmentcell motilitychemotherapeutic agentchemotherapydesigneffective therapygenetic regulatory proteinimprovedin vivoknock-downmouse modelnew therapeutic targetnovelphosphoproteomicsprotein activationprotein expressionscreeningskillsstandard of caretargeted treatmenttherapeutic targettranscription factortranslational studytumortumor growthtumor progressiontumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
T-cell lymphomas display shorter relapse intervals and poor overall survival. Targeted therapies for T-cell
lymphomas are lacking, and there is no established standard of care for patients at relapse. The limited
information on the specific molecular signals that are activated in T-cell lymphomas hampers the development
of effective therapies. Emergent research has demonstrated that aberrant activation of proteins involved in
actin organization is critical for cancer metastasis and tumor growth. The candidate preliminary studies
demonstrate that a large network of actin organizing proteins is activated during the development of T-cell
lymphoma. Also, the major actin regulatory protein Wiskott-Aldrich syndrome protein (WASp) increases the
dissemination and growth of a subtype of T-cell lymphoma, anaplastic large cell lymphoma (ALCL). These
preliminary findings are very exciting, as identified a major actin regulatory protein as key determinant for
lymphoma development. However, whether WASp also plays a role in lymphoma development in more
common and aggressive types of T-cell lymphomas needs to be determined. The candidate novel preliminary
findings demonstrate that WASp is expressed and activated in the most common type of T-cell lymphoma in
the United States, peripheral T- cell lymphoma, non-otherwise specified (PTCL-NOS). In addition, WASp
expression decreases the sensitivity of primary T-cell lymphoma cells to available chemotherapeutics,
suggesting a role of WASp in chemotherapy resistance. Moreover, WASp can activate downstream proteins
known to increase tumor proliferation and dissemination. Among these proteins, activation of lymphocyte
specific protein 1 (LSP1) and extracellular signal-regulated kinase (ERK) in T-cell lymphomas has been
validated. Importantly, ERK pathway can be inhibited with drugs that are currently in clinical trials for other
types of cancer. The central hypothesis is that WASp and its downstream signals (ERK and LSP1) are
therapeutic targets for patients with a diagnosis of T-cell lymphoma. In this proposal, I will evaluate 1) the role
of WASp and its downstream signals (ERK and LSP1) during lymphoma growth, 2) the role of WASp
dependent actin re-organization during T-cell lymphoma dissemination, 3) the signaling pathways that mediate
WASp-dependent chemotherapy resistance, and 4) the oncogenic role of WASp in-vivo using a mice model of
T-cell lymphoma with knock-down expression of WASp. The candidate long term career goal is to develop as a
successful independent physician-scientist with a research focus in the pathobiology of T-cell lymphomas. The
candidate career development plan is structured in three main components to help achieve its goals; 1) Gain
technical and clinical skills for translational studies on T-cell lymphomas, 2) Expand its knowledge related to
tumor progression and 3) Develop skills to become an independent scientist and write an R01 application to
the NCI.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Wiskott-Aldrich syndrome protein (WASp) signaling in the oncogenesis of T celllymphomas
-
批准号:10071043
-
项目类别:
-
资助金额:$8.25万
-
财政年份:2020
-
负责人:Carlos A. Murga-Zamalloa
-
依托单位:
海外基金